Vir Biotechnology Stock Has Doubled This Past Year. One Fund Just Bought 1.2 Million Shares
Key takeaways
- According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Boxer Capital Management bought 1,241,000 additional shares of Vir Biotechnology (NASDAQ:VIR).
- Boxer Capital Managements buy brought its Vir Biotechnology stake to 2.2% of 13F reportable AUM as of March 31, 2026.
- NASDAQ:TNGX: $227.53 million (29.9% of AUM)
Jonathan Ponciano, The Motley Fool Mon, May 18, 2026 at 3:07 AM GMT+7 4 min read VIR TNGX KOD CELC RVMD On May 15, 2026, Boxer Capital Management disclosed a purchase of 1,241,000 Vir Biotechnology (NASDAQ:VIR) shares, an estimated $9.89 million trade based on quarterly average pricing.
According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Boxer Capital Management bought 1,241,000 additional shares of Vir Biotechnology (NASDAQ:VIR). The estimated transaction value was $9.89 million, calculated using the average closing price from January 1 to March 31, 2026. The fund’s Vir Biotechnology position value increased by $12.95 million for the quarter, reflecting both additional shares and changes in the stock price.
Boxer Capital Managements buy brought its Vir Biotechnology stake to 2.2% of 13F reportable AUM as of March 31, 2026.